title: Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia.
abstract: Immunostimulatory CpG-containing oligodeoxynucleotides (CpG ODN) have a number of effects on B cells, including upregulation of immunogenic molecules, and, therefore, appear attractive as potential components of immunotherapy for B cell chronic lymphocytic leukemia (B-CLL). Previous in vitro studies investigating the effect of CpG ODN on B-CLL cells used serum-low conditions and did not account for the longer-half life of CpG ODN in vitro. The present study was designed to explore how the presence of serum and exposure time affect CpG ODN-mediated changes on B-CLL cells. The optimal concentration for CpG ODN-mediated effects in the presence of 100% serum or plasma was higher (10-20 microg/ml) than for serum-low conditions. Maximal CpG ODN-mediated effects required the presence of ODN for no longer than 3 hours. The inhibition of CpG ODN-mediated effects by serum correlated with lower uptake of ODN into B-CLL cells in the presence of serum. A threshold effect on biologic response was observed, with a given amount of ODN internalized, resulting in phenotypic changes. In conclusion, systemic short-term application of CpG ODN appears to be sufficient to induce phenotypic changes, but higher doses of CpG ODN than previously thought may be necessary because of inhibition of their uptake by serum.
authors.affiliation: The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.
authors.forename: Bernd
authors.initials: B
authors.lastname: Jahrsdörfer
authors.forename: Sue E
authors.initials: SE
authors.lastname: Blackwell
authors.forename: James E
authors.initials: JE
authors.lastname: Wooldridge
authors.forename: Christiana M
authors.initials: CM
authors.lastname: Taylor
authors.forename: George J
authors.initials: GJ
authors.lastname: Weiner
mesh_terms: D018899:CpG Islands / Q000235:genetics*; D016895:Culture Media, Serum-Free / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D018014:Gene Transfer Techniques; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods; D015448:Leukemia, B-Cell / Q000235:genetics*; D007945:Leukemia, Lymphoid / Q000235:genetics*; D009841:Oligonucleotides / Q000737:chemistry*; D010641:Phenotype; D013997:Time Factors; D015854:Up-Regulation
chemical_list: D016895:Culture Media, Serum-Free; D009841:Oligonucleotides